Apomorphine Hydrochloride and Dipivefrin Hydrochloride

• Generic Name: apomorphine
• Dosage Forms: n.a.
• Other Brand Names: Apokyn, APO-Go, APO-Go Pen, Uprima

Acute, intermittent treatment of episodes of hypomobility (i.e., “off” episodes, including end-of-dose “wearing off” and unpredictable “on-off” episodes) associated with advanced Parkinson’s disease (designated an orphan drug by FDA for this use).

Used as an adjunct to other antiparkinsonian agents (e.g., levodopa, oral dopamine receptor agonists).

Formerly used to induce vomiting in the early management of acute oral drug overdose and in certain cases of oral poisoning (dose: 5–6 mg sub-Q).

• Generic Name: dipivefrin ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Propine

Reduction of elevated IOP in patients with open-angle glaucoma. Used alone or in conjunction with other IOP-lowering drugs. May be used as initial therapy or for control of IOP in those patients who have not responded adequately to other antiglaucoma agents.

May be preferred as an alternative to topical epinephrine in some patients (e.g., those with cardiovascular disease) because of increased intraocular penetration (lower doses are needed) and resultant decreased adverse systemic effects (e.g., cardiovascular effects) compared with epinephrine.

Does not produce miosis, accommodative spasm, blurred vision, or night blindness. Less likely than epinephrine to cause adenochrome staining of contact lenses.

Has been used to reduce IOP in the treatment of other ocular conditions, including ocular hypertension and pseudoexfoliative, low-tension, and secondary (e.g., post-angle closure, pigmentary, traumatic, herpes zoster) glaucomas.